secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001665988-25-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.
- Diluted EPS $0.11 vs loss of $0.40; non-GAAP EPS $0.21, up 31% YoY on lower interest and equity compensation.
- Adjusted EBITDA $33.8M vs $34.5M; cash from operations $25.9M, up 71%.
- Reaffirmed FY2025 guidance: revenue $560-570M, Adjusted EBITDA $112-116M, non-GAAP EPS $0.64-0.68.
- Received FDA 510(k) clearance for TalisMann and StimTrial PNS systems in July 2025, addressing chronic nerve pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000166598825000016/0001665988-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000166598825000016/bvs-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001665988-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer